• Leydig cell tumors
  • Constitute 1 to 3 percent of testis tumors.
  • Ten percent are malignant. They are never malignant in prepubertal patients.
  • Malignancy is diagnosed by presence of metastases.
  • Histologic determination of malignancy unreliable.
• Sertoli cell tumors
  • Less than 1 percent of testis tumors.
  • Ten percent are malignant (determined by presence of metastases).

References

• Baniel J, Foster RS, Rowland RG, Bihrle R, Donahue JP: Testis cancer: Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153:976-980, 1995.
• Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH: The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to 1989). J Urol 153:85-89, 1995.
• Einhorn LH: Salvage therapy for germ cell tumors. Semin Oncol 21:47-51, 1994.
• Einhorn LH, Donohue JP: Advanced testicular cancer: Update for urologists. J Urol 160:1964-1969. 1998.
• Moller H, Skakkeback NE: Testicular cancer and cryptorchidism in relation to prenatal factors: Case control studies in Denmark. Cancer Causes Control 8:904-12, 1997.
• Nichols C, Loehrer P Sr: The story of second cancers in patients cured of testicular cancer: Tarnishing success of burnishing irrelevance. J Natl Cancer Inst 89:1304-1305, 1997.
• Wegner HEH, Hubotter A, Andresen R, Miller K: Testicular microlithiasis and concomitant testicular intraepithelial neoplasia. Int Urol Nephrol 30:313-315, 1998.

Please log-in or register in order to submit comments.

Powered by AkoComment!